Inflection’s pipeline programs were licensed from the Spanish National Cancer Research Centre (CNIO) following an extensive global in-licensing process. The CNIO has a global reputation for excellence in cancer research and has its own drug discovery program.


The pipeline comprises AUM302 (formerly IBL-302), partnered with AUM Biosciences, and IBL-202, selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 seriespan-PIM inhibitors currently in preclinical stages of development. Kinase inhibitors are an important new class of targeted therapy that modify specific cell signalling pathways that are involved in cancer disease processes. Kinase inhibitors are a highly successful class of novel treatments for cancer and have shown lower attrition rates as they advance through clinical development.



Search - Use spaces to separate your keywords
Inflection Biosciences. Suite 15, Anglesea House Carysfort Avenue, Blackrock,  Co. Dublin.  

 Company registration no. 509046.

© 2020 Inflection Biosciences.   Web Design by Webtrade